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1. Introduction
1.1. The importance of non-invasive evaluation of liver steatosis and fibrosis in virus C
infected patients
Chronic conditions of the liver represent an important public health issue. Whatever the na‐
ture of the aggression against the liver, it seems that it always follows the same pattern: in‐
flamation -> necrosis -> healing (fibrosis) -> regeneration (cirrhosis) -> dysplasia ->
hepatocellular carcinoma. An important link in this course of events is represented by fibro‐
genesis. On the other hand, there are more and more evidence that, in patients with chronic
hepatitis C, steatosis is a risk factor independently associated with necroinflammatory activ‐
ity and fibrosis progression.
At the moment, the gold standard in the evaluation of both liver fibrosis and steatosis is rep‐
resented by liver biopsy (LB), an invasive method with possible side effects. As a result,
most of the research done worldwide is focused towards developing other alternative, non-
invasive diagnosis methods, that would be capable to evaluate fibrosis and steatosis as accu‐
rately as possible.
Therefore, the following pages will present an evaluation of unidimensional transient elas‐
tography (TE) performance in the assessment of liver fibrosis and steatosis in patients suffer‐
ing from chronic viral hepatitis type C (HCV).
© 2012 Lupsor et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Liver biopsy – An imperfect gold standard
Liver biopsy was performed by P Ehrlich in 1883 and became a common exploration meth‐
od in 1958, when G Menghini introduced the first biopsy technique with a needle that was
named after him [1].
Liver biopsy provides a lot of information [2-6]:
• it represents the gold standard for a positive and differential diagnosis of diffuse liver diseases;
• provides important etiology data;
• allows for the evaluation of the necroinflammatory activity, evolutive stage (fibrosis) and
confirms if cirrhosis is present or not;
• helps establish the prognosis;
• identifies concomitent morphological alterations that may influence therapy response and
its evaluation (steatosis, iron overload, etc);
• it can determine treatment efficiency.
At the same time, one can not ignore the fact that liver biopsy has significant limitations:
possible complications, including mortality; important sampling errors; high cost; subjective
appreciations that may be due to important intra and interobserver variations.
Biopsy complications may vary in magnitude and frequency depending on the subjacent liv‐
er pathology. Among these can be listed: pain (epigastric area, right shoulder, right hypo‐
condrium); vagal response; hemorrhagic accidents (hemoperitoneum, hemobilia, liver
hematoma); bile peritonitis, bilioma; bacteremia; infections and abscesses; pneumothorax
and/or pleural reactions; hemothorax; arteriovenous fistula; subcutaneous emphysema; ad‐
verse reactions caused by the anesthetic; breaking of the biopsy needle; penetration of other
organs: lung, kidney, colon. The mortality associated with this technique is low, but it is
possible in 0.0088-0.3% of the cases [7-11].
The most significant problem encountered when interpreting a biopsy is represented by
samplig error. Considering the fact that the tissue sample obtained through liver biopsy rep‐
resents approximately 1/50.000-1/100.000 of the liver volume, it can be inadequate for the di‐
agnosis of diffuse liver conditions, as the histopathological changes may be spread unevenly
[5]. Even though liver biopsy is considered the standard exploration in the evaluation of liv‐
er diseases, it has an accuracy of only 80% in staging fibrosis and it can miss cirrhosis in 30%
of the cases [12]. For example, Ragev reported that in HCV patients, there is a discrepancy of
at least 1 stage between the right and left lobe in 33% of the patients [13]. At the same time,
Siddique observed that a difference of at least one stage between 2 samples (15 mm long) cut
from the same area occurs in 45% of the cases [14].
Considering all these observations, the results of the studies performed to validate a non-
invasive diagnosis method must be interpreted with caution, since they are compared with
an imperfect „gold standard”.
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Because of the limitations and invasive nature of liver biopsy, other non-invasive means are
being tested for the evaluation of diffuse hepatopathies, and implicitly of fibrosis and steato‐
sis as major prognosis factors in the evolution of the hepatopathy. Therefore, there is interest
in developing other methods, either serological or imaging, which are all non-invasive, in
order to determine the presence and degree of fibrosis, as well as of steatosis. One of these
methods is unidimensional transient elastography (Fibroscan).
3. The principle of unidimentional transient elastography
The divice consists of a special transducer, that is placed in the axis of a mechanical vibrator.
The vibrator generates pain-free vibrations that produce a train of elastic waves that will be
transmited through the skin and subcutaneous tissue to the liver. At the same time with acti‐
vating the vibration, the probe performs a number of ultrasound acquisitions (the same
process of emision-reception used in conventional ultrasonography), with a frequency of 4
kHz. Reports on the tissues deformation caused by elastic wave transmission can be formu‐
lated by comparing the succesive ultrasound (US) signals acquired in this manner. The time
necessary for the train of waves to propagate along the area of interest, as well as propaga‐
tion velocities are being measured. This way liver stiffness can be determined using the fol‐
lowing formula: E = 3ρVs2 (E – elasticity module, ρ – density, a constant of the material; Vs –
propagation velocity within the liver parenchyma). The more rigid the material, the higher
the velocity of propagation [15-17].
During the examination, the patient is lying down, face-up, with his right arm placed in hy‐
perextension and above the head for an adequate exposure of his right hypocondrium. The
probe is placed in contact with the patient’s skin, at the level of an intercostal space, in an
area of full liver dullness and avoiding any large vessels.
When the button on the probe is pushed, the vibration that will be transmitted through the
liver is activated. By analyzing tissue deformation report, the software of the equipment will
measure the liver stiffness (LS). The results are given in kiloPascals (kPa) and correspond to
a median value of 10 valid measurements. The machine can determine values between 2.5
and 75 kPa.
The monitor of the machine will display data regarding the patient’s identity, diagnosis,
name of the examining physician, the instantaneous value of liver stiffness (CS), the median
stiffness resulted from 10 valid measurements, the success rate (SR), as well as the variation
of the 10 values compared with the median value (IQR).
To be in agreement with the recommendations of the producer, the success rate must be at
least 60% and IQR must not exceed 30% of the median liver stiffness [16], even though it
seems that the best concordance with liver biopsy is obtained when this value does not ex‐
ceed 20% of the median [18].
There are no studies that especially focus on the issue of the variability of LS measurements
and therefore the interpretation of the results is done according to the experience of the ex‐
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aminer and the recommandations of the producer [19]. It is not known whether this variabil‐
ity is encountered only in the diseased liver or whether it is present in the healthy liver as
well and to what degree this affects the interpretation of the results. The cause of this prob‐
lem can be an inadequate technique or the liver pathology itself (for example, in macronod‐
ular cirrhosis, liver stiffness can be different in different areas of the liver). When there is a
high variability of the results, it is important to check whether the probe is placed perfectly
perpendicular on the thoracic wall, if the transmited vibration does not encounter the ribs
and if the waves are transmited vertically, strictly between the ribs. If the generated wave is
large, bifid or angulated, than the software of the machine will reconstruct the velocity
curve in different points of the wave and therefore lead to variations of the acquired values.
In order to obtain an accurate elastogram the transducer must be placed in the middle area
of the right lobe, avoiding contact with the ribs that may lead to vibration distorsion and
absorbtion [19].
The technique measures the stiffness of a volume that is equivalent with that of a cilinder of
1 cm in diameter and 4 cm in length (the measurement can be performed on a distance of 25
to 45 cm from the skin). This volume, representing about 1/500 of the liver volume, is at least
a 100 times larger than the one obtained through liver biopsy and it is therefore more repre‐
sentative for the whole liver parenchyma [20, 21].
The examination can be performed by a technician following a short period of training (ap‐
proximately 100 cases) [22-23], while the clinical interpretation of the results must always be
done by an expert who would consider the demographic data, the etiology of the disease
and the biochemical profile of the patient at the moment of the examination [21].
A multivariate analysis of the relationship between liver stiffness and fibrosis, necroinflam‐
matory activity and steatosis Showed, in some studies, that there is a significant correlation
with fibrosis, but no correlation with necroinflammatory activity and steatosis [16, 24]. Nev‐
ertheless, the authors of the initial concept acknowledged, following in vitro studies, that it
is unlikely that a single physical parameter (liver stiffness) would describe entirely a com‐
plex biological system in which fibrosis is only a part [15].
A prospective assessment of the role of the histopathological parameters seen in LB in ex‐
plaining the variance of liver stiffness was performed on 345 chronic hepatitis C patients
that all underwent liver biopsy [25]. First, LS correlated highly with the degree of fibrosis
assessed by liver biopsy,, but we also found a weak correlation with hepatic iron deposition
and steatosis and a mild correlation with activity. In multiple regression analysis, fibrosis,
activity, and steatosis independently influenced LSM. Iron deposition does not seem to in‐
fluence the liver stiffness in CHC patients. Fibrosis, activity, and steatosis together explained
62.4% of the variance of the LS. The three significant parameters uniquely explained 45.95%
of the amount of LS, with fibrosis making the most unique contribution (44.49%); the differ‐
ence of 16.25% (62.4%-45.95%) was accounted for by the joint contribution of the three pa‐
rameters. The size and the direction of the relationships suggest that higher LS values are
obtained for patients with advanced fibrosis, increased necroinflammatory activity and in‐
creased steatosis. Among these three, however, the stage of fibrosis is the single most impor‐
tant predictor, as suggested by the squared partial correlation [25].
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The prediction model computed from this study [25] can be expressed as follows:
Liver stiffness (log-transformed) = 0.493 + 0.180*fibrosis stage +0.034*steatosis + 0.033*activi‐
ty grade.
Therefore, our studies showed that fibrosis is indeed the main predictor of liver stiffness,
but the activity and steatosis cannot be neglected, and may explain the LS variability within
the same fibrosis stage.
4. Performance of TE for the noninvasive evaluation of liver fibrosis
HCV patients
The first condition that benefited from unidimensional transient elastography was chronic
hepatitis type C [21, 26].
4.1. The diagnosis of liver fibrosis stages
Studies performed on a large number of HCV patients indicate that the LS value is highly
correlated with the stage of fibrosis. The practical utility of the method is based on establish‐
ing cutoff values for each stage of fibrosis. A diagnosis of stage F ≥2, F ≥3 and F4 (cirrhosis)
is based on measurements of liver stiffness that vary, according to some studies, from 6.2 to
8.8 Kpa, 7.7 to 10.8 kPa and from 11 to 14.8 kPa (Table 1) [24, 26-30].
There are some meta-analyses addressing the issue of diagnosis performance of TE. Fifty
studies were included in the analysis performed by Friedrich Rust et al. The mean AUROC
for the diagnosis of significant fibrosis, severe fibrosis, and cirrhosis were 0.84, 0.89 and 0.94,
respectively [31]. In Stebbing’s meta-analysis, a total of 22 studies were selected, comprising
4430 patients, most of them suffering from a virus C liver infection. The pooled estimates for
significant fibrosis (≥F2) measured 7.71 kPa (LSM cutoff value) with a sensitivity of 71.9%
and a specificity of 82.4%, whereas for cirrhosis (F4) the results showed a cutoff of 15.08 kPa
with a sensitivity of 84.45% and a specificity of 94.69% [32].
It must be underlined that, in spite of the very good areas under the ROC curves, overlaps
of the stiffness values were registered in adjacent stages, especially for early fibrosis [33].
The increase of liver stiffness is higher between stage F2 (6.6 kPa) and F3 (10.3 kPa) of fibro‐
sis than between F1 (5.5 kPa) and F2 (6.6 kPa), a fact that is in agreement with the morpho‐
logical data according to which the increase in fibrotic tissue is more significant from F2 to
F3 than from F1 to F2 [12].
The diagnosis accuracy of TE is much better in predicting cirrhosis. In Friedrich-Rust metaa‐
nalysis [31], the AUROC mean for the diagnosis of cirrhosis was 0.94 and the performance
estimated by Talwalkar [34] was also very good: sensitivity 87%, specificity 91%, positive
probability rate 11.7, and negative probability rate 0.14 (95% CI 0.10-0.20).
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Fibrosis
Stage
Author Cutoff (kPa) Se(%) Sp(%) PPV(%) NPV(%) +LR -LR AUROC
F≥1 Ziol [24] - - - - - - - -
Castera [26] - - - - - - - -
Sporea [27] - - - - - - - -
Nitta [28] - - - - - - - -
Arena [29] - - - - - - - -
Kim SU [30] - - - - - - - -
F≥2 Ziol [24] 8.8 56 91 56 88 0.63 0.48 0.79
Castera [26] 7.1 67 89 48 95 6.09 0.37 0.83
Sporea [27] 6.8 59.6 93.3 98 30.1 - - 0.773
Nitta [28] 7.1 82.8 80.3 86 73.6 4.1 0.88
Arena [29] 7.8 83 82 83 79 4.58 0.20 0.91
Kim SU [30] 6.2 76 97.5 97.4 80 30.4 0.3 0.909
F≥3 Ziol [24] 9.6 86 85 93 71 5.76 0.16 0.91
Castera [26] 9.5 73 91 81 87 8.11 0.29 0.90
Sporea [27] - - - - - - - -
Nitta [28] 9.6 87.7 82.4 72.5 92.7 5 - 0.90
Arena [29] 10.8 91 94 92 73 11.27 0.07 0.99
Kim SU [30] 7.7 100 95.7 87.5 100 0 23.3 0.993
F4 Ziol [24] 14.6 86 96 97 78 23.05 0.14 0.97
Castera [26] 12.5 87 91 95 77 9.66 0.14 0.95
Sporea [27] - - - - - - - -
Nitta [28] 11.6 91.7 78 41.5 98.2 4.2 - 0.90
Arena [29] 14.8 94 92 73 98 11.27 0.07 0.98
Kim SU [30] 11 77.8 93.9 58.3 97.5 12.8 0.2 0.970
Table 1. Liver stiffness cutoff values for staging liver fibrosis using TE in HCV patients. Sensibility (Se), specificity (Sp),
positive predictive value (PPV) and negative predictive value (NPV) for each fibrosis stage (using Metavir scorring
system).
But it must not be forgotten that the cutoff values for predicting the stages of fibrosis were
chosen using the ROC curves in such a way that the sum of sensitivity and specificity is
maximum. The country where the study was performed was among the factors that influ‐
enced the diagnosis performance of TE [31]. Therefore, even though the cutoff values de‐
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fined for a certain population may be relevant, they may not be applicable in another
population where the incidence of fibrosis is different. Because of this, it is indicated that
each centre establishes its own cutoff values, in agreement with the prevalence of fibrosis
stages in that particular population, and calculates the performance of the method in rela‐
tion with those cutoff values. According to our experience on a number of 1138 HCV pa‐
tients that underwent liver biopsy, the predictive cutoff values for stages F1, F2, F3 and F4
are: 5.1kPa, 7.5kPa, 9.1kPa and 13,2kPa, with an AUROC of 0.836, 0.826, 0.933 and 0.973, and
diagnosis accuracy between 77 and 92.8% [35]. In table 2 are presented the liver stiffness cut‐
off values that predict each stage of fibrosis for the Romanian patients suffering from viral C
chronic hepatitis. The table also presents the sensitivity (Se), specificity (Sp), positive predic‐
tive value (PPV) and negative predicting value (NPV), false positive (FPR) and false nega‐
tive rate (FNR) the area under the ROC curve (AUROC) as well as the diagnosis accuracy
(DA) of these cutoff values. In our study, the adjusted AUROC according to the prevalence
of each individual stage of fibrosis did not significantly differ from the observed ones (0.847
for F≥1, p=1.00; 0.893 for F≥2, p=0.06; 0.945 for F≥3, p=0.34; 0.983 for F4, p=0.312), therefore
the cutoff values that we obtained may have a large applicability.
4.2. Monitoring disease progression
4.2.1. Diagnosis of liver cirrhosis. Prediction of portal hypertension and related complications
TE has a very good diagnosis accuracy in predicting cirrhosis (stage F4 Metavir), with areas
under ROC varying from 0.90 to 0.99 and cutoff values between 9-26.6 kPa [31], but there is
a high interest to determine whether the use of the machine’s entire specter of measure‐
ments (up to 75 kPa) can predict the clinical events characteristic to the evolution of cirrho‐
sis. Some authors [36] indicated, with a negative predictive value of over 90%, that the
suggestive values for predicting the presence of various complications are: 27.5 kPa for large
esophageal varices; 37.5 kPa for Child B and C cirrhosis; 49.1 kPa for ascites; 53.7 kPa for
hepatocarcinoma and 62.7 kPa for bleeding esophageal varices.
Portal hypertension is the main characteristic of liver cirrhosis, and the hepatic venous por‐
tal gradient (HVPG) is the best surrogate marker to assess its presence.
A positive strong correlation between liver stiffness and HVPG was reported in HCV pa‐
tients [37] and, afterwards, independently confirmed in another group of patients with se‐
vere fibrosis (Metavir F3-F4) [38]. The correlation was excellent for HVPG values lower than
10 or 12 mm Hg, but the linear regression analysis did not reveal exceptional results for
HVPG values >10 mm Hg or >12 mm Hg. This means that, even though TU may detect a
progressive elevation of the portal pressure, mainly because of an increase in intrahepatic
vascular resistance caused by the accumulation of extracellular fibrillar matrix, this method
can not entirely determine the extremely complex hemodynamic alterations that character‐
ize the delayed phase of portal hypertension [39]. As a result, some authors believe it is un‐
likely that elastography can be useful in monitoring the hemodynamic therapeutic response,
as the effect of the treatment is mainly mediated by the splanchnic circulatory changes [40].
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≥ F1; F0vsF1234 ≥ F2; F01vsF234 ≥ F3; F012vsF34 F4; F0123vsF4
Liver stiffness cutoff
value (kPa) 5.1 7.5 9.1 13.2
Se (%) 85.09 74.27 86.99 93.59
Sp (%) 65.45 82.95 88.51 92.71
+LR 2.46 4.36 7.57 12.84
-LR 0.23 0.31 0.15 0.07
PPV (%) 97.9 88.8 83.2 83.4
NPV (%) 18.7 63.9 91.2 97.4
FPR (%) 36.36 17.30 12.23 7.41
FNR (%) 13.86 25.59 12.55 6.41
Diagnosis accuracy (%) 85.01 77.34 87.63 92.87
Observed AUROC 0.836 0.860 0.933 0.973
Adjusted AUROC
according to the
prevalence of the
fibrosis stages
0.847 0.893 0.945 0.983
p (difference between
obs vs adj AUROC) 1.00 0.06 0.34 0.312
Table 2. Diagnostic performance of different cutoff values of liver stiffness in staging liver fibrosis in HCV Romanian
patients [35].
Regarding the relationship between liver stiffness and the presence of esophageal varices,
the area under the ROC curve for predicting the presence of varices varied between 0.76 and
0.84 [38, 41, 42]. Using cutoff values of 13.9 kPa, 17.6 kPa and 21.3 kPa, the sensitivity for
varices prediction was high (95%, 90% and 79%), but the specificity was relatively low (43%,
43% and 70%) [38, 41, 42]. There are studies that demonstrated a relationship between the
value of liver stiffness and the size of the varices [41, 42, 43], while other studies were not
able to demonstrate this correlation [38]. Using cutoff values of 19 and 30.5 kPa, the sensitiv‐
ity of TE for varices prediction was higher, but the specificity and the positive predictive
value were modest [41, 42]. TE did not provide better results than the serological markers
(like prothrombin time, thrombocytes [44] or FibroTest [45]), neither for varice detection (re‐
gardless of their grade), nor for the diagnosis of significant varices [41]. Yet, a predictive role
of liver stiffness in anticipating variceal bleeding cannot be excluded [43, 46].
These contradicting results may be caused by the heterogeneity of the studied populations,
the variable prevalence of varices (in general, but also of the large ones), the lack of prospec‐
tive validation (all the cited studies were cross-sectional studies) and the variability of the
cutoff values [47]. In conclusion, the evaluation of liver stiffness is not safe enough for the
detection and grading of esophageal varices in such a manner that it may replace upper di‐
gestive tract endoscopy in patients with cirrhosis, since the specificity and positive predic‐
tive value reported until now are too low to allow for a regular use of the method in clinical
practice.
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The literature data available on this topic are synthetized in table 3
Author etiology prev EV cutoff (kPa) Se Sp VPP VPN AUROC
HVPG VE VEM
Carion[37] HCV - 8.7a - - 90 81 90 81 0.92
Bureau[43] toate - 21b - - 90 93 91 90 0.94
Lemoine [48] HCV - 20.5b - - 63 70 35 88 0.76
-OH 34.9b - - 90 88 64 98 0.94
Vizutti [38] HCV 66% 17.6c - - 94 81 91 86 0.92
- 17.6 - 90 43 66 77 0.76
Kazemi [42] toate 45% - 13.9 - 95 43 91 57 0.84
- - 19 91 60 95 48 0.83
Castera [41] HCV 36% - 21.5 - 76 78 84 68 0.82
- - 30.5 77 85 92 54 0.85
HCV = hepatits C virus; -OH = etanol; EV = esophageal varices; LEV =large esophageal varices; Se = sensibility; Sp =
specificity; P/NPV =positive/negative predictive value; AUROC = area under the ROC curve; HVPG = Hepatic venous
pressure gradient (a HVPG ≥ 6 mm Hg; b HVPG ≥ 10 mm Hg; c HVPG ≥ 12 mm Hg).
Table 3. TE performance in EV diagnosis and HVPG prediction in liver cirrhosis patiens.
The huge potential of TE for cirrhosis patients was acknowledged ever since the method
was introduced, as it can serve as a fast and non-invasive screening toll in the assessment of
actual complications, it can estimate the long term risk and thus place the patient in a certain
risk category [49]. The first signs of this possibility were the outcome of a retrospective
study which found that the risk of a patient with hepatitis C for developing hepatocellular
carcinoma is 5 times higher in patients with a LS value above 25 kPa, at the moment of the
diagnosis [50]. Even more, a recent prospective study [51], that evaluated the role of liver
stiffness in predicting complications related to portal hypertension in cirrhosis patients,
demonstrated that a LS value < 21.1 kPa at diagnosis was as valuable as a HVPG<12 mmHg
in the selection of the patients who will not experiment clinical events.
4.2.2. Optimization of liver stiffness performance in the diagnosis of liver cirrhosis or its
complications
Based on the principle enounced by Pinzani et al, which states that a concordance between
two distinct noninvasive tests is needed for an accurate diagnosis [52], an association be‐
tween LS and serum noninvasive tests for liver fibrosis was used to improve the diagnostic
accuracy. Such an algorithm was proposed by the Bordeaux group [53] and it is based on the
concordance between FibroScan and FibroTest. Using this approach, cirrhosis could be diag‐
nosed with an accuracy of 93% and liver biopsy could be avoided for the diagnosis of cirrho‐
sis in almost 80% of cases.
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On the other hand, our group managed to demonstrate that the Lok Score and LS used to‐
gether as part of a noninvasive algorithm (see figure 1) can improve (78% diagnostic accura‐
cy) the noninvasive estimation of large esophageal varices in cirrhotic patients [54].
Figure 1. Proposition for a non-invasive algorithm for the assessment of esophageal varices in patients with liver cir‐
rhosis.
4.2.3. TE efficacy in hepatocellular carcinoma risk assessment
Early detection of hepatocellular carcinoma (HCC) in HCV patients represents an emerging
health problem. As a common practice, alpha-fetoprotein (AFP) is widely used for the diag‐
nosis of HCC, despite its low sensitivity and specificity [55]. Tateyama et al report AFP
above normal levels as a risk factor for the development of hepatocellular carcinoma in pa‐
tients infected with hepatitis C virus [56].
Besides AFP, it has been proven that LS values increase as the liver disease progresses, the
highest values being specific for cirrhotic patients with associated HCC [36]. The evidence
prove that the individual role of increased LS measurements and serological markers are
predictive biomarkers of HCC [57, 58]. The first risk evaluation of HCC development in
HCV patients using TE was first performed by Foucher et al in 2006, reporting a cut-off val‐
ue of 53.7 kPa [36]. Also, according to Akima T et al [59] liver stiffness as measured by TE is
a good predictor of HCC development in viral hepatitis, with serum total bilirubin ≥1.0
mg/dL significantly correlated with tumor development. The latest published results report
good diagnostic accuracy of LS in HCC prediction, for cut-off values ranging between 12.5
and 53.7 kPa [57,59,60]. However none of these studies have been designed to evaluate the
accuracy of more predictive parameters, others than LS. On the other hand, adding bio‐
markers and other variables (such as variance) to LS measurement could represent con‐
founding factors in the assessment of patients with liver cirrhosis and HCC [61]. This may
lead to an over- or under-estimation of the risk assessed by TE, so a new accuracy testing is
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needed. Nevertheless, increased LS seems to be a determinant of advanced cirrhosis, being
associated with decompensating episodes (high grade esophageal varices, bleeding, devel‐
opment of ascites) as well as with the presence of HCC [62], proving that increased LS alone
cannot be a good predictor of HCC.
On the other hand, Japanese studies also suggest that TE could be used as an indicator for the de‐
velopment of hepatocellular carcinoma in patients with virus C hepatitis [58, 63], the risk being 5
times higher in patients with a liver stiffness of over 25 kPa. Yet, these results must be confirmed
in prospective studies performed on larger groups of patients, in order to see whether liver stiff‐
ness can trully predict complication development in patients with compensated cirrhosis [21]. If
this fact is confirmed, elastography may serve as a non-invasive, quick screening modality which
could place the cirrhosis patient in a certain risk category [64].
4.2.4. Hepatitis C infection recurrence after liver transplant
ETU is useful in the appreciation of the severity of hepatitis C recurrence after transplanta‐
tion, thus reducing the number of liver biopsies [65]. In Carrion's study, for a cutoff value of
8.5 kPa, the sensitivity, specificity, negative predictive value and positive predictive value in
anticipating significant fibrosis were 90%, 81%, 79% and 92%. The important thing is that
none of the patients with a liver stiffness below that value presented severe fibrosis (F3), cir‐
rhosis (F4) or significant portal hypertension (HVPG ≥10 mm Hg). Furthermore only 6 (10%)
out of the 62 patients, having LS below the established threshold limit value,, did develop
portal hypertension, but in all cases it was a mild hypertension.
In Rigamonti's study [66], during the follow-up after transplantation, in 40 patients with
double biopsies (at 6 and 21 months), the liver stiffness changed in parallel with the stage of
fibrosis, having a sensitivity of 86 % and a specificity of 92% in predicting an increase in the
stage of fibrosis.
A recently published meta-analysis [67] showed that in patients undergoing transplantation for
HCV-related disease, TE appears to be a reliable diagnostic test for the exclusion of liver cirrho‐
sis. Furthermore, low TE values can reliable exclude cirrhosis in patients with recurrent HCV af‐
ter liver transplantation and liver biopsy may even be avoided in these situations. Among the
studies that evaluated significant fibrosis due to a recurrent HCV infection after liver transplan‐
tation, the pooled estimates were 83% for sensitivity, 83% for specificity, 4.95 for the positive like‐
lihood ratio, 0.17 for negative likelihood ratio and 30.5 for diagnostic odds ratio. For the studies
that assessed cirrhosis, the pooled estimates were 98% for sensitivity, 84% for specificity, 7 for
positive likelihood ratio, 0.06 for negative likelihood ratio, and 130 for diagnostic odds ratio[67].
5. Confounding factors influencing the interpretation of liver stiffness
values
Since the liver is self-contained in the non extensible Glisson’s capsule, stiffness is definitive‐
ly influenced by pressure that can be either hydrostatic or osmotic [68]. There are a few con‐
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ditions that may determine false results in situations where other factors, except from
fibrosis, are influencing liver stiffness.
Necroinflammatory activity proved to influence liver stiffness in patients with viral hepatitis,
causing an increase in stiffness in parallel with the grade of histological activity [29, 69, 70]. In
agreement with these results, the risk of overestimating the stage of fibrosis may occur in pa‐
tients with acute hepatitis or reactivated chronic hepatitis, if just the value of liver stiffness is con‐
sidered. Recent studies demonstrated that tissue alterations associated with acute hepatitis in a
patient with no liver disease history produce a significant growth of liver stiffness, sometimes
reaching cirrhosis values; this is due either to cellular intumescence or to severe cholestasis [71].
The contribution of these non-fibrotic changes upon liver stiffness was demonstrated by the pro‐
gressive reduction of liver stiffness parallel with the decrease of the transaminases [72, 73].
On the other hand, in patients with reactivated chronic hepatitis (therefore with preexisting
fibrosis), the increased stiffness is not caused by fibrosis alone, but also by the added cellular
intumescence [74].
From a practical perspective, it is important that the values of liver stiffness in patients with
acute hepatitis or in those with reactivated chronic hepatitis must be interpreted carefully,
within the patient's clinical and biochemical context [75]. In these patients, a certain diagno‐
sis of severe fibrosis or cirrhosis cannot be established. The right management in these cases
is to wait until the transaminases come back to normal and only when the potential involve‐
ment of inflammation is removed, the real status of fibrosis can be determined; it can thus be
established whether the event was an acute hepatitis on a diseased liver or a chronic hepati‐
tis with pre-existing fibrosis that was reactivated [76].
At the same time, in patients with acute hepatitis, the evaluation of liver stiffness at various
time intervals, can indicate the evolutive pattern of the condition, that may be characterized
either by evolution towards fulminant hepatitis (significant increase in LS), or by remission
(decrease in LS) [77].
Liver steatosis. The influence of steatosis on liver stiffness remains controversial. In some
studies, steatosis did not have a significant impact on liver stiffness, even after adjusting for
fibrosis stage [16, 24, 28]. Still, in these studies, the proportion of patients with severe steato‐
sis was too low to reliably quantify a possible influence and therefore further studies are
necessary to clarify this aspect.
We noticed from our experience that, after performing a stratified analysis of liver stiffness for
each stage of fibrosis, for the same grade of necroinflammatory activity (moderate-severe), the
presence of steatosis lead to a significant increase in LS from 5.89 ± 1.64 kPa to 7.15 ± 2.67 kPa for
those with stage F1 Metavir (p=0.004), and from 7.23±2.74 to 8.55±4.67 kPa for those with stage F2
(p=0.04) [78]. Besides, our studies have demonstrated that fibrosis is indeed the main predictor of
liver stiffness, but activity and steatosis cannot be neglected and may explain the LS variability
within the same fibrosis stage [25]. Afterwards, Ziol et al, using computer analysis of the micro‐
scopic image on a group of 152 patients, confirmed that steatosis clearly influences liver stiffness
independently from fibrosis, an influence that is insignificant in patients with cirrhosis, but im‐
portant in non-cirrhosis patients [79].
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Extra-hepatic  cholestasis.  The  impact  of  extrahepatic  cholestasis  on  liver  stiffness  was  re‐
cently demonstrated by Milloning [80] by evaluating cholestasis before endoscopic retro‐
grade cholangiopancreatography as well as 3 and 12 days after the procedure, in a study
group of  patients  with cholestasis  caused mainly by a neoplastic  invasion of  the biliary
tree. If initially liver stiffness had values close to cirrhosis values (a mean of 15.2 kPa), af‐
ter drainage, the LS decreased as low as 7 kPa, in parallel with a decrease in values of bi‐
lirubin of  2.8-2.9  mg/dl.  In  all  patients  that  underwent  biliary drainage,  the decrease of
liver stiffness correlated with that of the bilirubin values, with a mean of decrease of 1.2
±0.56  kPa for  a  reduction of  the  bilirubin  of  1g/dl.  The  relationship  between liver  stiff‐
ness and cholestasis was afterwards reproduced in the same study on an animal model
that underwent ligation of the biliary duct. This resulted in an elevation of liver stiffness
from 4.6 kPa to 8.8 kPa in the first 120 minutes after ligation and a decrease in stiffness
to 6.1 kPa within the first  30 minutes after decompression. In conclusion, it  is  indicated
that before an interpretation of the stiffness measurements is performed, an eventual ex‐
trahepatic cholestasis must be excluded using imaging investigations and lab tests.
Congestive heart failure may lead to an increased liver stiffness, with values similar to cirrho‐
sis, because of the elevated blood content of the liver, in 60% of the patients [80-84]. In the
context of cardiopulmonary conditions, TE may be relevant for the evaluation of treatment
efficacy, as liver stiffness decreases once cardiac compensation is achieved.
6. Optimizing the non-invasive diagnosis of portal hypertension using
spleen stiffness measurements
Splenomegaly is a common finding in liver cirrhosis that should determine changes in
spleen density as well, because of tissue hyperplasia and fibrosis [85, 86], and/or because of
portal and splenic congestion due to the splanchnic hyper-dynamic state [87]. These changes
might be quantified by elastography. Until recently, only magnetic resonance elastography
(MRE) was used with encouraging results in this respect [88]. The preliminary data showed
a highly significant correlation between liver and spleen sti฀ness in patients with portal hy‐
pertension, but, according to the authors, the validity of spleen stiffness as noninvasive
measure of portal venous pressure is not reliable enough [89].
6.1. Principle of TE for Spleen Stiffness Measurements (SSM) and technique assessment
Our group proposed for the first time the use of FibroScan® for spleen stiffness measure‐
ment (SSM) [90]. For the measurement itself we proposed the same procedure as for the liv‐
er stiffness measurement, with the sole exception that the patient had his left arm in
maximum abduction and the transducer was placed in the left intercostal spaces, usually on
the posterior axillary line. For better locating the splenic parenchyma, we also used ultra‐
sound guidance, so that we could choose the best location for performing the analysis.
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6.2. Efficacy of spleen stiffness measurements for the evaluation of the presence and the
grade of esophageal varices
In the above mentioned study, we demonstrated that spleen stiffness can be assessed using
transient elastography, the sole factor influencing the measurement being the spleen size.
Spleen stiffness increases as the liver disease worsens, from normal to chronic hepatitis and
to liver cirrhosis (figure 2).
Figure 2. A - Box plots of spleen stiffness values for controls (0), chronic hepatitis (1) and cirrhosis patients (2). The top
and the bottom of the boxes are the first and third quartiles, respectively. The length of the box thus represents the
interquartile range within which 50% of the values were located. The line through the middle of each box represents
the median. The error shows the minimum and maximum values (range); B - Graphic representation of the significant
increase of SSM in healthy controls and patients with chronic hepatitis and liver cirrhosis, respectively.
In liver cirrhosis patients, the spleen stiffness measurement, can predict the presence, but
not the grade of esophageal varices. Therefore, for a cutoff value of 46.4 kPa, we managed to
predict the presence of esophageal varices with a diagnostic accuracy of 80.45% and an AU‐
ROC of 0.781 (figure 3).
Figure 3. A - Box plots showing the increase of SSM in liver cirrhosis patients with esophageal varices as compared
with those without; B - ROC curve representation of SSM in distinguishing LC patients with or without EV.
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In another more recent study [91], another group demonstrated that SSM also correlates
with HVPG values, suggesting that this new elastographic technique may become a valua‐
ble noninvasive method for liver cirrhosis patients
6.3. Improving diagnostic accuracy for esophageal varices by modifying the SSM
calculation algorithm
Regarding the spleen stiffness measurement itself, we observed that the results seem to be
influenced by the intrinsic characteristics of the machine (FibroScan). Regardless of the vari‐
ceal status of the patients, or the grade of the varices, SSM reached the maximum value that
can be measured by the machine (75 KPa). This is an important drawback, because we have
to face a significant interpolation between the patients groups. If the FibroScan had been
able to determine values beyond 75 KPa, we may have obtained better figures. In order to
overcome this situation, we cooperated with the manufacturer of the device for developing
a new calculation algorithm, not available on the commercial device, which allows stiffness
measurements of up to 150 kPa. In a validation study [54], using the new calculation algo‐
rithm, we could differentiate between any classes of esophageal varices, except V1 vs V2
(p<0.005) and could select patients with V3 (V012 vs V3 = 63.49 vs 116.08 kPa, p<0.005), the
ones that are at higher risk for bleeding (figure 4).
7. Noninvasive evaluation of liver steatosis using Controlled Attenuation
Parameter (CAP)
Even though liver stiffness provides an alternative to liver biopsy for fibrosis staging, it can
identify very important histologic features such as macrovesicular steatosis, ballooned hepa‐
tocytes, inflammation, etc [68].
Figure 4. Boxplots representing mean SSM values according to the esophageal varices grade using the original (A) or
the modified (B) calculation algorithm.
Knowing that fat interferes with ultrasound propagation, a novel attenuation parameter has
been developed to detect and quantify liver steatosis. This parameter is based on the ultra‐
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sonic properties of the radio-frequency back propagated signals acquired by the Fibroscan
[92]. It is called controlled attenuation parameter (CAP). This ultrasonic attenuation coeffi‐
cient is an estimate of the total ultrasonic attenuation (go-and-return path) at the central fre‐
quency of the regular or M Fibroscan® probe, i.e. at 3.5 MHz, and is expressed in dB.m−1.
CAP is evaluated using the same radio-frequency data and the same region of interest, as
the region used to assess the LSM. CAP is only appraised if the acquisition is ‘‘valid’’. There‐
fore, CAP is guided by vibration-controlled transient elastography (VCTE), which ensures
that the operator automatically obtains an ultrasonic attenuation value of the liver [92, 93].
The device is used to assess, at the same time, LS (which is related to liver fibrosis) and CAP
(which is related to liver steatosis).
Even though relatively few studies have been published on this topic [92, 93, 94,95] the pre‐
liminary results showed that CAP is a promising non-invasive tool to detect steatosis in
CHC patients.
In the study conducted by Sasso et al, the CAP performance was appraised on 115 patients,
taking the histological grade of steatosis as reference. CAP was significantly correlated to
steatosis with an AUROC equal to 0.91 and 0.95 for the detection of more than 10% and 33%
of steatosis, respectively.
A study performed recently on 615 HCV patients, who underwent both Fibroscan (®) and
liver biopsy showed in multivariate analysis, that CAP was related to steatosis, independ‐
ently of fibrosis stage (which was related to LS. The AUROCs of the were 0.80, 0.86 and
0.88 respectively, for predicting a fatty overload of more than 11%, 33%, and 66%, respec‐
tively.  CAP  also  exhibited  a  good  ability  to  differentiate  steatosis  grades  (Obuchowski
measure = 0.92) [96].
CAP is evaluated using the same radio-frequency data and the same region of interest, as
the region used to assess the liver stiffness for fibrosis quantification. Preliminary studies
performed in our department have found significantly different CAP values for different
steatosis grades and AUROCs of 0.830 and 0.85 respectively, for the prediction of a hepatic
fat content over 33% and 66%, respectively [97].
8. The advantages of TE in liver steatosis, fibrosis and cirrhosis diagnosis
Compared with other diagnosis indicators or predictive models based on lab tests, the eval‐
uation of fibrosis using elastography has some important advantages [98,99]:
• It is easy to use; noninvasive; pain-free; does not require anesthesia or hospitalization and
is therefore easily accepted by the patient;
• It is quick, the time needed for the examination being very short;
• It is not influenced by concomitant conditions;
• It is operator independent;
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• The liver volume used to evaluate fibrosis is 150-400 times higher than the volume ob‐
tained through liver biopsy.
As far as the evaluation of liver steatosis is concerned, in comparison to other modalities,
CAP is non-invasive, quantitative, non-ionizing, and inexpensive. Furthermore, the proce‐
dure is easy to perform, even by an operator who does not have any radiological skills and
provides immediate results. The procedure is also machine-independent and does not re‐
quire corrections to be made for gain, frequency, focusing or beam diffraction, and is also
not subject to operator interpretation. In addition, CAP has been shown to efficiently detect
steatosis at a level of ≥ 10%, which is more sensitive than other imaging modalities. Com‐
pared to a liver biopsy, CAP is less prone to sampling error as it explores a liver volume
∼100 times larger [92, 93].
9. Limitations of TE
Liver fibrosis can not be evaluated by TE in 5-8 % of the cases. Some of the possible causes
for this are listed below [16]:
• obesity (an ultrasound machine may be used in order to find the best window and thus
increase the ability to measure liver stiffness in overweight patients);
• a narrow intercostal space;
• ascites (vibrations are not transmitted through fluid);
• the quality of the liver parenchyma and other liver structures;
• large vascular structure present in the acquisition window (may lead to false results).
The failure of TE varies according to different authors from 2.4% to 9.4% [16, 21, 24, 36, 74,
64, 100]. In a study performed on 2114 patients [101], liver stiffness could not be determined
in 4.5% of the cases and multivariate analysis showed that the only element associated with
measurement failure is a body mass index over 28. Yet, with more experience, one may real‐
ize that a thick thoracic wall is more likely to be a limiting factor for a failed measurement
than the growth of the body mass index in itself [102].
Technical solutions regarding the design of the probe were investigated lately, in order to
overcome these limitations. Recently a new probe became available, that was specially de‐
signed for obese patients, with a central frequency of 2.5% MHz (compared with the 5MHz
probe that is usually used), and that is able to determine liver stiffness on a distance of 35-75
mm from the skin (while the normal probe is able to do that on distance of 25 to 45 cm).
With the help of this new transducer, it was possible to obtain valid measurements in 49% of
the patients with a BMI ≥30 kg/m2, in which the usual probe failed to determine the LS
[103].
As far as predicting steatosis in HCV patients is concerned, CAP has further validation in
larger populations and by independent teams, since there are rather few studies published
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until now. Another important limitation is that CAP cannot be used with measurements tak‐
en from the XL probe, which is a novel probe designed to assess liver stiffness in overweight
and obese patients [75,76]. Thus, CAP needs to be developed to work with the XL probe.
10. Conclusions
The possibility of concomitant assessment of liver fibrosis (using liver stiffness measure‐
ment) and of steatosis (using CAP) makes Fibroscan a promising non-invasive tool for as‐
sessing and quantifying both fibrosis and steatosis, that may broaden the spectrum of non-
invasive methods used for the investigation and follow-up of patients with chronic hepatitis
C. But it is important that interpretation of the liver stiffness values be done by an experi‐
enced physician and always within the clinical and biochemical context of the patient.
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